RxDoctor Payments Data

Connie Nguyen, MD

Family Medicine · Westminster, CANPI 1851471023

Payments from drug & device makers

$20,969in general payments, 2019–2025

Across 989 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Gilead$1K
  • Amarin Pharma, Inc.$1K
  • AstraZeneca$1K
  • plus $9K from 53 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$20,84199%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen119$3,013
AbbVie(2 entities)182$2,259
Lilly USA, LLC68$2,129
Gilead27$1,497
Amarin Pharma, Inc.71$1,461
AstraZeneca(2 entities)56$1,239
Novo Nordisk63$866
Boehringer Ingelheim36$760
GSK32$697
Phathom Pharmaceuticals, Inc.13$576
Astellas Pharma US Inc28$525
Nestle Healthcare Nutrition Inc.26$483
Pfizer28$431
Dexcom, Inc.19$374
Merck21$366
Aimmune Therapeutics, Inc.19$365
Kowa Pharmaceuticals America, Inc.20$357
Mylan Specialty L.p.8$262
Ironwood Pharmaceuticals, Inc12$249
Ardelyx, Inc.12$236
Oyster Point Pharma, Inc.5$204
Novartis9$197
Radius Health, Inc.8$182
Otsuka America Pharmaceutical, Inc.7$168
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$165
Esperion Therapeutics, Inc.8$164
Abbott8$160
Sun Pharmaceutical Industries Inc.5$148
Scilex Pharmaceuticals Inc.5$147
Xeris Pharmaceuticals, Inc.6$130
Regeneron Healthcare Solutions, Inc.2$99
Viatris Specialty LLC4$86
Vivus LLC4$83
Electromed, Inc.6$80
Arbor Pharmaceuticals, Inc.4$71
Sanofi Pasteur Inc.4$68
Exact Sciences3$58
Hikma Pharmaceuticals USA3$51
Takeda Pharmaceuticals U.S.A., Inc.3$49
Kaleo, Inc.1$46
Shield Therapeutics Inc2$46
Cequr Corporation2$44
Sumitomo Pharma America, Inc.2$36
IBSA Pharma Inc.2$36
Eyevance Pharmaceuticals LLC2$35
Philips North America LLC1$29
Vifor Pharma, Inc.1$25
Emergent Biosolutions Inc.1$23
Neotract Inc.1$22
Exeltis, USA Inc.1$20
Sanofi-aventis U.S. LLC1$19
Therapeuticsmd, Inc.1$18
Sunovion Pharmaceuticals Inc.1$17
Currax Pharmaceuticals LLC1$17
Lundbeck LLC1$17
VYNE Pharmaceuticals Inc.1$17
Seqirus USA Inc1$17
Cipher Pharmaceuticals US LLC1$16
Optinose US, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,969 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$286,091
Medicare patients
166
Services billed
5,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab209$339,480
Evenity (2 Syringes)Romosozumab-Aqqg105$246,497
TrulicityDulaglutide169$230,462
Synjardy XrEmpagliflozin/Metformin Hcl211$225,307
MounjaroTirzepatide107$175,526
VascepaIcosapent Ethyl258$153,954
LinzessLinaclotide153$138,478
CreonLipase/Protease/Amylase82$138,121
OzempicSemaglutide98$120,438
ZenpepLipase/Protease/Amylase75$116,109
JardianceEmpagliflozin118$113,342
MyrbetriqMirabegron122$100,718
ProcritEpoetin Alfa21$62,862
FarxigaDapagliflozin Propanediol64$57,882
RybelsusSemaglutide29$55,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Evenity (2 Syringes)$3,013$585,977314 claims
Lilly USA, LLCTrulicity, Mounjaro$2,129$405,987276 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Tradjenta$760$398,654379 claims
AbbVieLinzess, Creon, Restasis, Namzaric$2,259$315,919261 claims
Novo NordiskOzempic, Rybelsus$866$176,289127 claims
Aimmune Therapeutics, Inc.Zenpep$365$116,10975 claims
Astellas Pharma US IncMyrbetriq$525$100,718122 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,239$65,30976 claims
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Shingrix$697$49,060140 claims
PfizerEliquis$431$31,99332 claims
MerckBelsomra$366$10,74813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →